Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea · Delayed Price · Currency is KRW 26,300
-50 (-0.19%)
Jun 4, 2026, 3:19 PM KST
Daihan Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 26,978 | 27,644 | 33,759 | 28,426 | 24,961 | 22,670 |
Depreciation & Amortization | 10,498 | 9,221 | 7,282 | 8,663 | 9,208 | 11,411 |
Loss (Gain) From Sale of Assets | -35.02 | -31.38 | -58.03 | -22.53 | 9.4 | -41.28 |
Loss (Gain) From Sale of Investments | -49.61 | -274.01 | -303.6 | -288.69 | - | - |
Provision & Write-off of Bad Debts | -33.3 | 24.34 | 17.05 | 10.8 | -33.29 | -142.8 |
Other Operating Activities | 4,005 | 2,406 | 2,115 | 4,194 | 2,632 | 7,386 |
Change in Accounts Receivable | -1,309 | 199.83 | -385.22 | 437.93 | -2,172 | -10.94 |
Change in Inventory | -5,999 | -8,134 | -3,194 | 1,271 | -4,407 | 2,969 |
Change in Accounts Payable | -435.15 | 1.13 | 526.47 | -877.61 | 2,997 | -389.71 |
Change in Other Net Operating Assets | -7,552 | -5,452 | -4,115 | -2,954 | -4,194 | -3,234 |
Operating Cash Flow | 26,068 | 25,604 | 35,643 | 38,860 | 28,999 | 40,617 |
Operating Cash Flow Growth | -26.07% | -28.16% | -8.28% | 34.00% | -28.60% | 20.79% |
Capital Expenditures | -22,944 | -25,123 | -15,801 | -21,280 | -8,621 | -11,850 |
Sale of Property, Plant & Equipment | 35.04 | 31.4 | 58.04 | 22.53 | - | 41.66 |
Investment in Securities | -8,640 | -12,521 | -56,883 | 3,235 | 8,635 | 283.86 |
Other Investing Activities | 0 | 0 | 0 | 25 | 180 | 10 |
Investing Cash Flow | -31,549 | -37,612 | -72,626 | -17,998 | 193.48 | -11,515 |
Short-Term Debt Repaid | - | - | - | -2,500 | -200 | -1,000 |
Long-Term Debt Repaid | - | -37.12 | -38.79 | -4,080 | -16,817 | -4,300 |
Total Debt Repaid | -32.34 | -37.12 | -38.79 | -6,580 | -17,017 | -5,300 |
Net Debt Issued (Repaid) | -32.34 | -37.12 | -38.79 | -6,580 | -17,017 | -5,300 |
Repurchase of Common Stock | - | - | - | - | -3,418 | - |
Dividends Paid | -5,195 | -5,195 | -4,329 | -3,752 | -2,108 | -2,108 |
Other Financing Activities | -18.95 | - | - | - | - | - |
Financing Cash Flow | -5,246 | -5,232 | -4,368 | -10,332 | -22,543 | -7,408 |
Foreign Exchange Rate Adjustments | 270.4 | -89.82 | 1,152 | 113.04 | 441.94 | 671.96 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 | -0 |
Net Cash Flow | -10,457 | -17,329 | -40,199 | 10,644 | 7,092 | 22,367 |
Free Cash Flow | 3,124 | 481.53 | 19,841 | 17,580 | 20,378 | 28,767 |
Free Cash Flow Growth | -84.44% | -97.57% | 12.86% | -13.73% | -29.16% | 1.77% |
Free Cash Flow Margin | 1.48% | 0.23% | 9.72% | 8.97% | 11.06% | 16.78% |
Free Cash Flow Per Share | - | 81.89 | 3374.38 | 2989.79 | 3405.01 | 4794.57 |
Cash Interest Paid | 2.91 | 2.69 | 1.81 | 52.47 | 582.23 | 451.55 |
Cash Income Tax Paid | 7,146 | 7,913 | 8,028 | 8,656 | 8,869 | 3,247 |
Levered Free Cash Flow | -1,113 | -4,364 | 12,013 | 13,570 | 17,249 | 25,715 |
Unlevered Free Cash Flow | -1,112 | -4,363 | 12,014 | 13,603 | 17,620 | 26,009 |
Change in Working Capital | -15,295 | -13,385 | -7,168 | -2,123 | -7,777 | -665.87 |